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Background: Protozoan Leishmania parasites are responsible for a 
range of clinical infections that represent a substantial challenge for 
global health. Amphotericin B (AmB) is increasingly used to treat 
Leishmania infection, so understanding the potential for resistance to 
this drug is an important priority. Previously we described four 
independently-derived AmB-resistant L. mexicana lines that exhibited 
resistance-associated genetic lesions resulting in altered sterol 
content. However, substantial phenotypic variation between these 
lines, including differences in virulence attributes, were not fully 
explained by these changes. 
Methods: To identify alterations in cellular metabolism potentially 
related to phenotypic differences between wild-type and AmB-
resistant lines, we extracted metabolites and performed untargeted 
metabolomics by liquid chromatography-mass spectrometry. 
Results: We observed substantial differences in metabolite 
abundance between lines, arising in an apparently stochastic manner. 
Concerted remodeling of central carbon metabolism was not 
observed; however, in three lines, decreased abundance of several 
oligohexoses was observed. Given that the oligomannose mannogen 
is an important virulence factor in Leishmania, this could relate to loss 
of virulence in these lines. Increased abundance of the reduced forms 
of the oxidative stress-protective thiols trypanothione and glutathione 
was also observed in multiple lines. 
Conclusions: This dataset will provide a useful resource for 
understanding the molecular basis of drug resistance in Leishmania, 
and suggests a role for metabolic changes separate from the primary 
mechanism of drug resistance in determining the phenotypic profile 
of parasite lines subjected to experimental selection of resistance.
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Introduction
Parasites of the genus Leishmania place a high burden on public 
health, with clinical manifestations ranging from self-healing 
cutaneous lesions to life-threatening visceral leishmaniasis. 
Efforts to control this disease rely heavily on chemothera-
peutic agents, but the traditional front-line class, pentavalent 
antimonials, suffers from both high toxicity and increasing 
drug resistance1. Another widely used compound, miltefosine, 
has also shown a trend of decreasing clinical efficacy2,3. In this 
context, the antifungal polyene amphotericin B (AmB) is 
increasingly the treatment of choice for leishmaniasis, with 
the introduction of liposomal formulations serving to increase 
efficacy and reduce adverse effects4.
The mechanism of action of AmB is not fully understood but 
involves specific binding to ergosterol within parasite and 
fungal membranes, leading to disruption of membrane function 
either through the formation of aqueous pores or by sequester-
ing ergosterol within the membrane5,6. Resistance to this com-
pound is not yet widespread in Leishmania populations but 
has been documented both in clinical isolates7–9 and through 
experimental selection or genetic manipulation10–17. However, 
the introduction of single-dose regimens of liposomal AmB risks 
enhancing conditions conducive to resistance selection in the 
field. Resistance is generally associated with mutations in the 
ergosterol biosynthesis pathway. Recently, we described four 
AmB-resistant L. mexicana lines selected independently 
in vitro and subjected to phenotypic, genomic and transcrip-
tomic characterization15. All four demonstrated lesions within 
the ergosterol biosynthesis pathway. Specifically, AmBRA/cl1 
demonstrated a point mutation in the gene sterol C5-desaturase 
(LmxM.23.1300), whereas AmBRB/cl2, AmBRC/cl3 and 
AmBRD/cl2 all demonstrated structural variants leading to 
greatly reduced expression of sterol C24-methyltransferase 
genes (LmxM.36.2380 and LmxM.36.2390). Sterol analysis by 
gas chromatography-mass spectrometry revealed corresponding 
changes in the sterol composition of these strains, and genetic 
complementation studies demonstrated that both genes 
played key roles in AmB resistance. In addition, resistance in 
AmBRB/cl2 was partially the result of deletion of the 
miltefosine transporter gene (LmxM.13.1530), also associated 
with miltefosine cross-resistance in this line. Loss of miltefosine 
transporter function was previously reported in an AmB- 
resistant line13, and an RNAi knockdown screen in the related 
parasite Trypanosoma brucei revealed that reduced expression 
of the T. brucei ortholog of LmxM.13.1530 is also associated 
with AmB resistance18.
Whilst this study confirms an important role for sterol changes 
in AmB resistance, other studies suggest that additional cellular 
processes may play a role. Increased expression of genes 
associated with defense against reactive oxygen species (ROS) 
has been found in drug-resistant L. infantum19, and overexpres-
sion of genes of the pentose phosphate pathway (PPP, an important 
source of NADPH reducing equivalents) decreased AmB 
sensitivity20. Whilst previous studies in Leishmania14 and Candida 
albicans21 have associated AmB resistance with increased 
sensitivity to oxidative stress, no strain in our study15 exhib-





) nor menadione (which leads to the generation of intracel-
lular ROS). Therefore, it is possible that the lack of substantial 
ROS hypersensitivity in these lines is explained by compensatory 
metabolic changes in redox metabolism.
Another unanswered question relates to virulence phenotypes 
in the AmB-resistant lines. Only one of the four lines, 
AmBRC/cl3, retained similar capacity to infect macrophages 
to that of the parental wild-type line (as well as retaining viru-
lence in a mouse model of cutaneous infection). However, 
resistance in this line was associated with a disruption of sterol 
C24-methyltransferase function highly similar to that found 
in AmBRB/cl2 and AmBRD/cl215. This suggests that loss of 
virulence may result from a separate change, possibly arising 
spontaneously during adaptation to long-term culture in vitro. 
Genomic and transcriptomic analyses alone did not provide a 
clear indication of any such mechanism.
Therefore, we wished to determine whether some of these 
phenotypes resulted from changes in cellular metabolism. We 
performed untargeted metabolomics analysis using liquid 
chromatography-mass spectrometry (LC-MS), to detect differ-
ences between AmB-resistant lines and the parental wild-type 
line. Whilst numerous changes were observed, many of these 
were not conserved between lines, suggesting a stochastic 
origin rather than selection in response to drug pressure. 
Nevertheless, evidence of adaptation to oxidative stress was 
observed, and changes to oligosaccharide abundance suggest 
a possible metabolic basis for the variation in virulence between 
these lines.
Results
Metabolomics analysis reveals evidence of stochastic changes in 
metabolism in independently-derived AmB-resistant L. mexicana 
strains
After filtering data for peak quality, 319 metabolites were 
identified on the basis of mass, of which 232 showed an effect 
of strain on metabolite abundance (one-way ANOVA with 
Benjamini Hochberg correction, P < 0.05)22. Within these 
metabolites, a Tukey’s Honest Significant Difference test was 
performed to determine metabolites significantly differing 
(P < 0.05) from the wild-type parental line. Limited overlap 
was evident between AmBR strains, and principal component 
analysis further demonstrated a lack of similarity of lines 
(Figure 1A). Of 83 metabolites showing increased abundance in 
at least one AmBR strain relative to wild-type, 47 (57%) were 
unique to an individual strain, with 56 out of 139 metabolites 
(40%) showing repression in one strain only (Figure 1B). 
Only one metabolite, succinate, showed universally increased 
abundance in AmBR strains relative to the parental line, albeit 
modestly (30–57% increase). These data suggest that the 
majority of metabolic phenotypes are governed by stochastic 
changes during cell culture, as opposed to the effects of selection 
pressure with AmB.
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Figure 1. Overall trends in untargeted metabolomics data. A) Principal component analysis performed on range-scaled data. The 319 
identified metabolites that met filtering criteria (see Methods) were all included. B) Venn diagrams showing overlap of metabolites induced or 
repressed across different AmB-resistant lines. Metabolites included are those with Benjamini-Hochberg-corrected p-value (q-value) < 0.05 
for ANOVA, and a Tukey’s Honest Significant Difference test comparing to wild-type with p-value < 0.05.
Changes in carbohydrate and energy metabolism
Since overexpression of PPP enzymes leads to greater tolerance 
of oxidative stress and AmB resistance20, we investigated whether 
AmBR lines had a higher abundance of PPP intermediates. 
Amongst detectable PPP metabolites, none showed a higher 
abundance compared to WT, and some decreases were noted 
(Figure 2). This was reflected in the fact that NADPH abun-
dance was unchanged (Figure 2). As repression of mitochon-
drial activity in Candida albicans fungi leads to reduced ROS 
generation in response to AmB treatment23, we also looked for 
evidence of broader restructuring of energy metabolism. Whilst 
there was little evidence of generally altered abundance of 
intermediates in either glycolysis or the tricarboxylic acid (TCA) 
cycle in any AmBR line, both lactate and succinate showed 
increases across all lines (Figure 2). Succinate is an end product 
of fermentative metabolism in Leishmania24 and given the 
general trend towards decreased abundance of acetyl CoA 
(the first committed step of the TCA cycle), this may suggest 
a modest shift towards fermentation over respiration in these 
lines.
Therefore, changes in central carbon metabolism were confined 
largely to individual metabolites rather than whole pathways. 
In contrast, amongst putative oligosaccharides identified 
(3–6 hexose units – longer polymers extend beyond the 
detectable size range using this platform), there was a consist-
ent pattern of decreased abundance in three out of four lines 
(AmBRA/cl1, AmBRB/c2 and AmBRD/c2), whilst no changes 
were observed in AmBRC/cl3 (Figure 3). As different hexose 
isomers are indistinguishable by mass and standards for these 
compounds were not included, we are unable to determine 
explicitly the identity of these oligohexoses, but since a mannose 
polymer, mannogen, is a highly abundant storage carbohydrate 
in Leishmania25, it is likely that these are oligomannoses. Further 
evidence of this can be seen in the similar pattern of decreases in 
GDP-mannose, which is mannose donor during mannogen 
synthesis26. While this pattern did not extend to a putative 
di-hexose, this could be a disaccharide other than di-mannose 
(although the retention time did not match to the isomeric 
disaccharide sucrose, included as a standard).
Several metabolites relating to lipid metabolism were detected, 
including 23 with differential expression compared to WT in at 
least one line22. Given the abundance of isomers of lipid 
compounds, the lack of available standards, and the fact that many 
of these have very similar retention times, one cannot confidently 
assign identities to these compounds. Nevertheless, 18 showed 
altered abundance in AmBRB/cl2, of which 15 were decreased. 
As a homozygous deletion of the miltefosine transporter, a 
phospholipid flippase, was previously detected in this line15, we 
note that several metabolites show greater changes in abundance 
in AmBRB/cl2 than in other lines.
Changes in amino acid and polyamine metabolism
Of 319 metabolites putatively identified in this dataset, the largest 
annotated group was “amino acid metabolism” (101 metabolites). 
Of these, 66 showed significant differences from the parental 
line in at least one AmBR line, but overall the pattern was highly 
variable, including with respect to the 11 proteogenic amino 
acids identified (Figure 4, note that while stereochemistry cannot 
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Figure 2. Metabolite intensity plots for metabolites involved in carbohydrate and energy metabolism. Mean intensities across four 
biological replicates are shown, with error bars representing standard deviation. Black points represent intensities of individual replicates.
Figure 3. Metabolite intensity plots for metabolites relating to mannogen synthesis. Metabolites were identified as di- to hexa-hexoses 
on the basis of mass, and may be oligomannans, as described in the text. Mean intensities across four biological replicates are shown, with 
error bars representing standard deviation. Black points represent intensities of individual replicates.
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Figure 4. Heatmap of fold changes in amino acid intensity. Proteogenic amino acids with a Benjamini-Hochberg-corrected p-value 
(q-value) < 0.05 for ANOVA, and at least one Tukey’s Honest Significant Difference test comparing to wild-type with p-value < 0.05 are 
included (note that L- and D- isomers cannot be distinguished by this LC-MS method). Fold changes are in comparison with wild-type 
L. mexicana, with red representing increased abundance, and blue representing a decrease.
be determined using this method, these are presumed L-amino 
acids as found in proteins). A previous study indicated that 
proline was increased in response to selection for resistance to 
multiple antileishmanial compounds in L. donovani, including 
AmB27. Proline has previously been described as having 
ROS-scavenging activity28. Here, however, there was a general-
ized trend towards deceased proline abundance (significant in 
AmBRB/cl2 and AmBRD/cl2), with no increases.
One of the most important molecules for defense against 
oxidative stress is dihydro-trypanothione, the reduced form 
of trypanothione that is oxidized to trypanothione disulfide in 
several ROS detoxification reactions. Two peaks were initially 
identified as trypanothione, one with a mass-to-charge ratio 
(m/z) of 361.65 and retention time of 12.41 min, the other with 
an m/z of 723.30 and a retention time of 19.34 min. A peak for 
trypanothione was not found in the standards mix (despite this 
molecule being included), preventing differentiation on the 
basis of retention time. However, the 12.41 min peak was of 
higher quality, and moreover whilst the major m/z detected at 
12.41 min was 361.65 (likely resulting from double ionization of 
trypanothione, mass 723.86), an additional m/z of 723.30 (likely 
resulting from single ionization) was also detected at this 
same retention time, supporting the 12.41 min peak as the true 
trypanothione peak. For both peaks, however, a strong increase 
in abundance was noted in AmBRA/cl1, AmBRC/cl3 and 
AmBRD/cl2. No change was observed in trypanothione disulfide, 
the more abundant form of trypanothione, suggesting that the 
reduced/oxidized trypanothione ratio was increased in these 
lines even if the overall trypanothione pool itself may not have 
greatly increased. However, spontaneous oxidation during 
metabolite extraction is feasible, and dedicated methods aimed 
at reducing redox changes during sample preparation would be 
required to probe redox status more deeply29.
Trypanothione arises from the ligation of the polyamine 
spermidine and two molecules of glutathione (Figure 5). 
Polyamines themselves are poorly detected by the LC-MS sys-
tem used. However, N-acetylputrescine, a derivative of the sper-
midine synthesis intermediate putrescine, did not show increases 
corresponding with those of trypanothione (Figure 5). Likewise, 
S-adenosylmethionine, which is converted into S-adenosyl-5’-(3-
methylthiopropylamine), the aminopropyl donor used to create 
spermidine from putrescine, showed decreased abundance in 
AmBRB/cl2 and AmBRD/cl2 (Figure 5). Furthermore, arginine 
and ornithine, the upstream precursors of polyamine synthesis, 
actually showed decreased abundance in AmBRA/cl1, AmBRB/
cl2 and AmBRD/cl2 (Figure 5). Glutathione, the ROS-reactive 
thiol precursor of trypanothione, showed a similar, albeit more 
modest, pattern of increases in its reduced form to trypan-
othione itself (Figure 5). Glutathione is a tripeptide of L-cysteine, 
L-glutamate and glycine. Of these, L-glutamate showed 
modest increases in AmBRB/cl2 and AmBRD/cl2, but 
overall, the pattern of increases did not match that of reduced 
glutathione. Unlike trypanothione, the disulfide (oxidized) form 
of glutathione was not detected. Therefore, whether the increase 
in reduced glutathione results from a more reduced state of the 
glutathione pool or an overall increase in its abundance cannot be 
determined.
Discussion
Previously, to characterize the molecular basis of AmB 
resistance in Leishmania parasites, we selected resistance in 
four independent L. mexicana lines. In these lines, we deter-
mined a role for mutations in the genes sterol C5-desaturase 
(LmxM.23.1300) and sterol C24-methyltransferase (LmxM.36.2380/
LmxM.36.2390), correlating with altered sterol profile15. 
However, as changes in sterol profile did not fully explain differ-
ences in phenotypic traits, including virulence, we investigated 
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Figure 5. Changes in trypanothione biosynthesis. A) Metabolite intensity plots for metabolites involved in trypanothione biosynthesis. Mean 
intensities across four biological replicates are shown, with error bars representing standard deviation. Black points represent intensities of 
individual replicates. B) The trypanothione biosynthesis pathway.
broader metabolic alterations in these lines. Whilst numerous 
changes were observed, many of these were inconsistent between 
lines. This emphasizes the importance of testing multiple lines, 
since many of these changes may spontaneously arise during 
long term culture in vitro. Furthermore, the lack of an increase in 
proline metabolism differs from previous observations27, 
although as these were made in L. donovani this may reflect 
species-specific differences in drug response. Overall, 11 metabo-
lites showed differences from the parental wild-type conserved 
across all AmBR lines. However, these may reflect adaptation 
to long term culture, as the parental wild-type was isolated from 
an infected mouse shortly before selection began. To account for 
this, experiments can be performed comparing resistant lines to 
parasites cultured in parallel in the absence of drug. In this case, 
however, spontaneous changes arising in the wild-type during 
culture may further complicate analysis. Therefore, in the ideal 
scenario, both types of wild-type control (parental and long-term 
culture) should be used.
Overall, whilst numerous changes were observed, these were 
often modest in magnitude. One pathway that has previously been 
examined with respect to drug resistance in Leishmania is the 
pentose phosphate pathway20. Theoretically, increased flux in 
this pathway could increase the NADPH pool, leading to a more 
robust defense against oxidative stress. Baseline abundance of 
PPP metabolites in the absence of drug does not appear to be an 
adaptation to AmB, although differences may emerge in the 
presence of drug-induced stress, such as a greater capacity to 
increase flux in response to AmB. In contrast large increases in 
both dihydro-trypanothione and reduced glutathione abundance 
were observed. Increases in the reduced thiol pool could result 
from either decreased consumption (due to lower baseline ROS 
generation) or increased reduction rate. For both molecules, 
reduction is an NADPH-dependent, cytosolic process. Hence the 
fact that NADPH is unchanged could suggest that production of 
NADPH is increased through a PPP-independent mechanism. 
A cytosolic malic enzyme has been described in L. mexicana30, 
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and would represent an alternative means of NADPH generation, 
although neither its substrate malate, nor its product pyruvate, 
showed altered abundance. Hence the mechanism leading 
to increased reduction of the thiol pool is unclear. Ovothiol, 
another redox-active thiol found in Leishmania, was detected but 
was not observed to increase in AmB-resistant lines.
Likewise, there is little evidence of broad changes in central 
carbon metabolism, and whilst there do appear to be general 
increases in lactate and succinate abundance, this could also 
be an adaptation to the high glucose content of the HOMEM 
culture medium used in this study. Nevertheless, given the 
documented importance of mitochondrial metabolism and ROS 
production in drug sensitivity23, the balance of glycolytic and 
respiratory metabolism in drug-resistant Leishmania merits 
further investigation.
Another area of carbon metabolism showing substantial changes 
is in lipid composition. pHILIC LC-MS metabolomics is 
limited in its ability to resolve and identify lipid compounds. 
Nevertheless, these data reveal a number of changes specific 
to AmBRB/cl2, which carries a homozygous deletion in the 
phospholipid flippase LmxM.13.1530, responsible for AmB- 
miltefosine cross-resistance. Mutations in the L. infantum 
ortholog of this gene have previously been associated with AmB 
resistance13, but the mechanism is unclear, although notably 
increased membrane fluidity is known to affect AmB activity31. 
Given the potential for mutations in this gene to cause cross 
resistance to two major antileishmanial compounds, it will be 
useful to characterize this line further using a lipid-focused 
metabolomics method as previously described13. High-throughput 
RNAi screening in T. brucei identified multiple flippase- 
encoding genes required for AmB sensitivity18, strengthening the 
link between loss of flippase activity and AmB resistance.
An important observation from our previous study was that 
despite almost total loss of the dominant sterol in wild-type 
L. mexicana, ergosta-5,7,24(28)-trienol, and replacement with 
sterols lacking C24-methylation, the line AmBRC/cl3 retained 
wild-type infectivity both in primary macrophages and 
in vivo15. In contrast, AmBRB/cl2 and AmBRD/cl2, lines exhib-
iting highly similar loss of sterol C24-methylation due to 
disrupted sterol C24-methyltransferase expression, showed 
lack of infectivity in macrophages, suggesting that loss of 
virulence arises through a mechanism unrelated to sterol changes. 
Mannogen, a carbohydrate storage polymer comprised of 
D-mannose (an epimer of D-glucose), is essential for virulence32. 
Whilst larger polymers of mannose exceed the upper detected 
mass threshold of the LC-MS method used here, we observed 
consistent decreases in several oligo-hexoses (3-6 hexose units), 
as well as GDP-mannose, the mannose donor molecule during 
mannogen biosynthesis. Previously, we observed similar changes 
in a transketolase deletion mutant of L. mexicana, which were 
confirmed to have similar decreases in large molecular weight 
carbohydrate polymers33. As this line was avirulent in vivo, this 
suggests that similar mannogen-related changes in AmBR lines 
could be responsible for lack of virulence. As mannogen is not 
required for growth in vitro, it is likely that these changes arose 
spontaneously during long term selection, unrelated to sterol 
changes. Whilst notably there are fewer changes overall in 
the virulent line, AmBRC/cl3, than in the other AmBR lines, 
nonetheless this suggests that loss of oligomannan content may be 
an important consideration in assessing virulence of parasite lines 
derived through similar methods.
Overall, therefore, these data suggest a picture where high 
variability arises largely in a stochastic fashion during experimen-
tal selection. The basis of this variability is not clear, although 
aneuploidy in these lines was correlated with widespread 
differences in steady-state gene expression15, as similarly reported 
elsewhere34,35. This may have complex effects on the metabo-
lome. Many of these changes are modest, and therefore unlikely 
to have strong effects on drug sensitivity. By contrast, increased 
trypanothione abundance is likely to have a stronger role in 
these lines, either in direct defense against drug-induced ROS 
or in supporting tolerance of resistance-related changes in sterol 
composition. On the other hand, spontaneous changes may 
impact virulence independent of the resistance mechanism itself, 
making assessment of the effects of resistance selection on 
virulence harder to interpret. As this is key to understanding the 
likelihood of such mutations emerging in the clinical context, 
it will be important to monitor for changes in pathways such as 
mannogen synthesis when determining the basis of viru-
lence changes in drug resistant lines. As CRISPR-Cas9-based 
methods increase the feasibility of precise genome editing in 
Leishmania spp.36,37, it may be useful to replicate resistant-
related mutations de novo on the parental background. A better 
understanding of the relationship between sterol profile and 
fitness is crucial to estimating the risk of emergent resistance 
associated with AmB-based treatment programs in the elimination 
of leishmaniasis as a public health threat.
Methods
Sample extraction
Derivation of AmB-resistant lines from parental L. mexicana 
M379 was described previously15 (MNYC/BZ/62/M379 was 
originally isolated from Sumichrast’s vesper rat in 1962, Belize, 
and was a gift from Professor Graham Coombs). L. mexicana 
was cultured in HOMEM medium (Gibco cat. no 041-96499M) 
supplemented with 10% fetal bovine serum (Gibco cat. no. 
10500-64) at 25 °C. Prior to sample extraction, parasite cell lines 
grown in the presence of AmB (Sigma cat. no. A2942) (400 nM 
for AmBRA/cl1 and AmBRB/cl2, 200 nM for AmBRC/cl3 and 
AmBRD/cl2; wild-type parasites were cultured in the absence 
of drug) were diluted to approximately 105 parasites/ml and 
incubated for three days without AmB until parasites reached 
mid-log phase (5–10 × 106 parasites/ml), at which point cells 
were counted and 108 parasites were taken for metabolite 
extraction. Cultures were rapidly cooled to < 10 °C in a dry ice- 
ethanol bath with rapid agitation to avoid freezing, and samples 
were kept at 4 °C for the remaining stages of extraction, based 
on the method of t’Kindt and colleagues29. Parasites were 
sedimented by centrifugation (1,250 × g, 10 min), resuspended 
in ice-cold PBS and sedimented again (1,900 × g, 10 min) 
before resuspension in extraction solvent (1:3:1 v/v/v chloroform:
methanol:water). Extraction solvent was also added to empty 
tubes to act as blank samples. All samples were subjected to rapid 
agitation for 1 hr, before centrifugation at 17,000 × g, 10 min to 
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remove cellular debris. Supernatants were retained and stored 
at -80 °C under argon prior to analysis. Four replicates were 
obtained from independently grown cultures for each cell line. 
A pooled sample was produced as a quality control containing 
equal amounts of each sample, topped up with further extraction 
solvent.
Liquid chromatography-mass spectrometry
LC-MS analysis was performed at Glasgow Polyomics. 
Separation of metabolites was performed by hydrophilic interac-
tion liquid chromatography (HILIC) using the Dionex UltiMate 
RSLC system (Thermo Fisher Scientific) with a ZIC-pHILIC 
column (Merck Sequant). Column temperature was maintained 
at 30 °C during separation, with elution of samples using a linear 
gradient between two mobile phase solvents, solvent A (20 mM 
ammonium carbonate in water) and solvent B (acetonitrile). An 
initial A:B solvent ratio of 20:80 was gradually altered to 
80:20 over a 15 min period, after which the gradient was 
changed to 95:5 as rapidly as possible and held for 2 min. After 
returning the gradient to 20:80 as rapidly as possible, this was 
held for a further 7 min. The flow rate was 0.3 ml/min, with a 
10 μl injection volume. Samples were maintained at 4 °C prior 
to injection. Sample order was randomized, with pooled sample 
run every four samples to allow for assessment of instrument 
reproducibility over time.
Mass spectrometry was performed using a Thermo Orbitrap 
Exactive (Thermo Fisher Scientific), operating in polarity switch-
ing mode. The following settings were used: the resolution was 
50,000, the m/z ratio was 70–1,400, the automatic gain control 
target was 106, the probe temperature was 150 °C and the 
capillary temperature was 275 °C. Flow rates were as follows 
(in arbitrary units): 40 for sheath gas, 5 for auxiliary gas, 1 for 
sweep gas. Samples were ionized by electrospray ionization 
(ESI). Positive mode ionization was performed with a source 
voltage of +4.5 kV, a capillary voltage of +50 V, a tube voltage 
of +70 V, and a skimmer voltage of +20 V. Negative mode 
ionization was performed with a source voltage of -3.5 kV, a 
capillary voltage of -50 V, a tube voltage of -70 V, and a skim-
mer voltage of -20 V. Mass calibration was performed with each 
polarity prior to every analysis batch using Thermo Calmix 
standards for m/z < 1,400 (mixture of Pierce LTQ Velos ESI 
Positive Ion Calibration Solution, cat. no. 88323, and Pierce 
Negative Ion Calibration Solution, cat. no. 88324), with addi-













, m/z 89.0244, for 
negative ESI). These low-mass contaminants were used to apply 
lock-mass correction to each analytical run, to enhance calibration 
stability.
Data analysis
Initial metabolite identification from raw data, and relative 
quantification using peak area, were performed using the mzMatch 
(v2.0) package in R38 and IDEOM software (v19)39. Puta-
tive metabolite identification corresponds for the most part to 
Metabolite Standards Initiative (MSI) level 2 (mass only), whereas 
metabolites matching in retention time to an included standard 
correspond to level 1, as indicated in the underlying data22,40. 
Peaks having an area with root squared deviation across pooled 
samples > 50% were excluded, as were those with a retention 
time < 4 min (due to poor resolution) those identified as peptides 
(due to poor reproducibility), and those not matched to a 
metabolite. Peaks were subjected to initial filtering in which 
poor quality peaks were manually removed (performed in a 
blinded fashion in which metabolite names were unknown). 
Data were then log-transformed (log
10
(intensity + 1)) and a one-
way ANOVA test was performed, followed by a Tukey’s Honest 
Significant Difference post hoc test to compare sample groups. 
A Benjamini-Hochberg multiple comparisons procedure was 
used to adjust p-values from the initial ANOVA. All statistical 
analysis was performed in R (v.3.4.4), and plots were generated 
using ggplot2 (v3.1.1)41 and gplots (v3.0.1.1)42 R packages.
Data availability
Underlying data
Raw data for the metabolomics experiment along with assay 
details, Accession number MTBLS1167: https://identifiers.org/
metabolights:MTBLS1167
Full data for identified metabolites in wild-type and amphotericin 
B-resistant Leishmania mexicana parasites, figshare: https://doi.
org/10.6084/m9.figshare.10059710.v1
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Amphotericin B (AmB) is used in the treatment of the tropical disease leishmaniasis. Through its 
interaction with ergosta-type sterols, AmB disrupts membrane function in Leishmania parasites. In 
previous work the corresponding author’s team and other researchers have independently shown 
that mutation in any of several gene loci encoding different enzymes required for sterol ring or 
side-chain modification(s) leads to altered sterol compositions and links strongly to selection of 
AmB-resistant parasites. However, other genetic alterations have also been associated with 
decreased sensitivity to AmB and in laboratory-selected ‘sterol-altered’, AmB-resistant cell lines 
differences in parasite infectivity to macrophages or virulence within mouse models have been 
reported. Thus, in the current work Barrett and Pountain used metabolomics to study changes in 
cellular metabolism in four independently-selected AmB-resistant cell lines for which the same 
group had characterised phenotype, genotype and transcriptome relative to ‘wild type’ parent. 
 
Whilst the results from Pountain’s metabolomics analysis provide little evidence, at this point, for 
central metabolic changes (outside of sterol metabolism) consistently associated with AmB 
resistance or which adequately explain phenotype variations between mutants, this is an 
interesting data set for those working (or seeking to work) in the area(s) of trypanosomatid 
metabolism and drug resistance. For instance, the current health burden from leishmaniasis is 
such that new medicine development and insight into how human-infectious Leishmania species 
generally readily develop drug-resistant phenotypes are critical. Over many years Barrett’s team 
have pioneered the development of robust procedures for metabolite extraction and analysis 
from trypanosomatid parasites; their approaches thus, provide an excellent basis for others to 
standardise their metabolomics methods against. Similarly, it could be pertinent to determine how 
often changes in carbohydrate abundance are associated with decreased virulence. The open 
access presentation of datasets, such as the current one, should only therefore help in cost-
effective new medicine development for leishmaniasis.
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Poutain and Barrett have carried out a metabolomic study of amphotericin B resistance in 
Leishmania. They studied 4 mutants that were previously sequenced. Three genes were 
associated with resistance but the resistance levels could not be fully explained by these 
mutations hence this metabolomic study in order to better understand resistance. 
  
This lab is a world leader in metabolomics studies. In this study, however, this approach was only 
moderately useful. Yet it is important to report since others who may have been interested by this 
approach may think about something else for studying AMB resistance. Indeed, Wellcome Open 
Research will publish those types of studies. 
  
This manuscript provides evidence that metabolite abundance is very cell line dependent and not 
related to the mode of action of the drug. Is that the norm or something special related to either 
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the parasite or the drug used? 
  
The authors indicate that metabolites related to lipid metabolism showed altered abundance in 
particular in the B mutant with the miltefosine transporter deleted. This is of interest and 
additional studies (e.g. by manipulating the MT gene in a cleaner background) may help in 
studying lipid metabolism in the context of AmB resistance.
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